Jorieke Elisabertha Hermina Bergman

Jorieke Elisabertha Hermina Bergman

Auto-generated profile, based on publicly available information

Jorieke Elisabertha Hermina Bergman

Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2011 in Journal of Medical Genetics
Verified
Journal Article
Closed access
PDF file
JBJ E H Bergman
J E H Bergman
NJN Janssen
N Janssen
LHL H Hoefsloot
L H Hoefsloot
MJM C J Jongmans
M C J Jongmans
RHR M W Hofstra
R M W Hofstra
CRC M A van Ravenswaaij-Arts
C M A van Ravenswaaij-Arts
Background: CHARGE syndrome is a highly variable, multiple congenital anomaly syndrome, of which the complete phenotypic spectrum was only revealed after identification of the causative gene in 2004. CHARGE is an acronym for ocular coloboma, congenital heart defects, choanal atresia, retardation of growth and development, genital hypoplasia, and ear anomalies associated with deafness. This typical combination of clinical features is caused by autosomal dominant mutations in the CHD7 gene. Objective: To explore the emerging phenotypic spectrum of CHD7 mutations, with a special focus on the mild end of the spectrum. Methods: We evaluated the clinical characteristics in our own cohort of 280 CHD7 positive patients and in previously reported patients with CHD7 mutations and compared these with previously reported patients with CHARGE syndrome but an unknown CHD7 status. We then further explored the mild end of the phenotypic spectrum of CHD7 mutations. Results: We discuss that CHARGE syndrome is primarily a clinical diagnosis. In addition, we propose guidelines for CHD7 analysis and indicate when evaluation of the semicircular canals is helpful in the diagnostic process. Finally, we give updated recommendations for clinical surveillance of patients with a CHD7 mutation, based on our exploration of the phenotypic spectrum and on our experience in a multidisciplinary outpatient clinic for CHARGE syndrome. Conclusion: CHARGE syndrome is an extremely variable clinical syndrome. CHD7 analysis can be helpful in the diagnostic process, but the phenotype cannot be predicted from the genotype.

27 March 2012 in Human Mutation
Verified
Journal Article
Closed access
PDF file
NJNicole Janssen
Nicole Janssen
JBJorieke E. H. Bergman
Jorieke E. H. Bergman
MSMorris A. Swertz
Morris A. Swertz
LTLisbeth Tranebjaerg
Lisbeth Tranebjaerg
MLMarianne Lodahl
Marianne Lodahl
LHLies H. Hoefsloot
Lies H. Hoefsloot
CHD7 is a member of the chromodomain helicase DNA‐binding (CHD) protein family that plays a role in transcription regulation by chromatin remodeling. Loss‐of‐function mutations in CHD7 are known to cause CHARGE syndrome, an autosomal‐dominant malformation syndrome in which several organ systems, for example, the central nervous system, eye, ear, nose, and mediastinal organs, are variably involved. In this article, we review all the currently described CHD7 variants, including 183 new pathogenic mutations found by our laboratories. In total, we compiled 528 different pathogenic CHD7 alterations from 508 previously published patients with CHARGE syndrome and 294 unpublished patients analyzed by our laboratories. The mutations are equally distributed along the coding region of CHD7 and most are nonsense or frameshift mutations. Most mutations are unique, but we identified 94 recurrent mutations, predominantly arginine to stop codon mutations. We built a locus‐specific database listing all the variants that is easily accessible at www.CHD7.org. In addition, we summarize the latest data on CHD7 expression studies, animal models, and functional studies, and we discuss the latest clinical insights into CHARGE syndrome. Hum Mutat 33:1149–1160, 2012.

8 January 2014 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
IBIngeborg Barisic
Ingeborg Barisic
LOLjubica Odak
Ljubica Odak
M:Maria :oane
Maria :oane
EGEster Garne
Ester Garne
DWDiana Wellesley
Diana Wellesley
DTDavid Tucker
David Tucker
Oculo-auriculo-vertebral spectrum is a complex developmental disorder characterised mainly by anomalies of the ear, hemifacial microsomia, epibulbar dermoids and vertebral anomalies. The aetiology is largely unknown, and the epidemiological data are limited and inconsistent. We present the largest population-based epidemiological study to date, using data provided by the large network of congenital anomalies registries in Europe. The study population included infants diagnosed with oculo-auriculo-vertebral spectrum during the 1990–2009 period from 34 registries active in 16 European countries. Of the 355 infants diagnosed with oculo-auriculo-vertebral spectrum, there were 95.8% (340/355) live born, 0.8% (3/355) fetal deaths, 3.4% (12/355) terminations of pregnancy for fetal anomaly and 1.5% (5/340) neonatal deaths. In 18.9%, there was prenatal detection of anomaly/anomalies associated with oculo-auriculo-vertebral spectrum, 69.7% were diagnosed at birth, 3.9% in the first week of life and 6.1% within 1 year of life. Microtia (88.8%), hemifacial microsomia (49.0%) and ear tags (44.4%) were the most frequent anomalies, followed by atresia/stenosis of external auditory canal (25.1%), diverse vertebral (24.3%) and eye (24.3%) anomalies. There was a high rate (69.5%) of associated anomalies of other organs/systems. The most common were congenital heart defects present in 27.8% of patients. The prevalence of oculo-auriculo-vertebral spectrum, defined as microtia/ear anomalies and at least one major characteristic anomaly, was 3.8 per 100 000 births. Twinning, assisted reproductive techniques and maternal pre-pregnancy diabetes were confirmed as risk factors. The high rate of different associated anomalies points to the need of performing an early ultrasound screening in all infants born with this disorder.

25 February 2015 in World Journal of Urology
Verified
Journal Article
Open access
PDF file
JBJorieke E. H. Bergman
Jorieke E. H. Bergman
M:Maria :oane
Maria :oane
MVMartine Vrijheid
Martine Vrijheid
APAnna Pierini
Anna Pierini
RNRien J. M. Nijman
Rien J. M. Nijman
HWHermien E. K. de Walle
Hermien E. K. de Walle
Hypospadias is a common congenital malformation. The prevalence of hypospadias has a large geographical variation, and recent studies have reported both increasing and decreasing temporal trends. It is unclear whether hypospadias prevalence is associated with maternal age.

16 November 2013 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
EVEcaterina Vasluian
Ecaterina Vasluian
CSCorry K. Van Der Sluis
Corry K. Van Der Sluis
AEAnthonie J van Essen
Anthonie J van Essen
JBJorieke E H Bergman
Jorieke E H Bergman
PDPiet Dijkstra
Piet Dijkstra
HWHermien E K de Walle
Hermien E K de Walle
Reported birth prevalences of congenital limb defects (CLD) vary between countries: from 13/10,000 in Finland for the period 1964–1977 to 30.4/10,000 births in Scotland from 1964–1968. Epidemiological studies permit the timely detection of trends in CLD and of associations with other birth defects. The aim of this study is to describe the birth prevalence of CLD in the northern Netherlands.

17 September 2010 in Brain
Verified
Journal Article
Closed access
PDF file
EMEva Morava
Eva Morava
RWRon A. Wevers
Ron A. Wevers
VCVincent Cantagrel
Vincent Cantagrel
LHLies H. Hoefsloot
Lies H. Hoefsloot
LALihadh Al-Gazali
Lihadh Al-Gazali
DLDirk J. Lefeber
Dirk J. Lefeber
Cerebellar hypoplasia and slowly progressive ophthalmological symptoms are common features in patients with congenital disorders of glycosylation type I. In a group of patients with congenital disorders of glycosylation type I with unknown aetiology, we have previously described a distinct phenotype with severe, early visual impairment and variable eye malformations, including optic nerve hypoplasia, retinal coloboma, congenital cataract and glaucoma. Some of the symptoms overlapped with the phenotype in other congenital disorders of glycosylation type I subtypes, such as vermis hypoplasia, anaemia, ichtyosiform dermatitis, liver dysfunction and coagulation abnormalities. We recently identified pathogenic mutations in the SRD5A3 gene, encoding steroid 5α-reductase type 3, in a group of patients who presented with this particular phenotype and a common metabolic pattern. Here, we report on the clinical, genetic and metabolic features of 12 patients from nine families with cerebellar ataxia and congenital eye malformations diagnosed with SRD5A3-congenital disorders of glycosylation due to steroid 5α-reductase type 3 defect. This enzyme is necessary for the reduction of polyprenol to dolichol, the lipid anchor for N-glycosylation in the endoplasmic reticulum. Dolichol synthesis is an essential metabolic step in protein glycosylation. The current defect leads to a severely abnormal glycosylation state already in the early phase of the N-glycan biosynthesis pathway in the endoplasmic reticulum. We detected high expression of SRD5A3 in foetal brain tissue, especially in the cerebellum, consistent with the finding of the congenital cerebellar malformations. Based on the overlapping clinical, biochemical and genetic data in this large group of patients with congenital disorders of glycosylation, we define a novel syndrome of cerebellar ataxia associated with congenital eye malformations due to a defect in dolichol metabolism.